Megan E Kozisek

Summary

Publications

  1. ncbi request reprint Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies
    Megan E Kozisek
    Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198 5800, United States
    Pharmacol Ther 117:30-51. 2008
  2. ncbi request reprint The differential regulation of BDNF and TrkB levels in juvenile rats after four days of escitalopram and desipramine treatment
    Megan E Kozisek
    Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, 985800 Nebraska Medical Center, Omaha, NE 68198 5800, USA
    Neuropharmacology 54:251-7. 2008
  3. pmc Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies
    Megan E Kozisek
    Department of Pharmacology and Experimental Neuroscience, 985800 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE 68198 5800, USA
    J Neurosci Methods 163:83-91. 2007

Detail Information

Publications3

  1. ncbi request reprint Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies
    Megan E Kozisek
    Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198 5800, United States
    Pharmacol Ther 117:30-51. 2008
    ..Antidepressant treatments elevate activity-dependent neuronal plasticity by activating BDNF, thereby gradually restoring network function and ultimately mood...
  2. ncbi request reprint The differential regulation of BDNF and TrkB levels in juvenile rats after four days of escitalopram and desipramine treatment
    Megan E Kozisek
    Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, 985800 Nebraska Medical Center, Omaha, NE 68198 5800, USA
    Neuropharmacology 54:251-7. 2008
    ..The serotonergic nervous system matures earlier than the noradrenergic system, which may explain why escitalopram, but not desipramine, increases BDNF and TrkB levels...
  3. pmc Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies
    Megan E Kozisek
    Department of Pharmacology and Experimental Neuroscience, 985800 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE 68198 5800, USA
    J Neurosci Methods 163:83-91. 2007
    ..Thus, the pharmacokinetic properties of DMI varies with the age of the animal and dosing of DMI and needs to be carefully adjusted in order to have appropriate brain levels of the drug...